Drugs Made In America Acquisition II (NASDAQ:DMII) Shares Up 0.2% – Here’s Why

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII)’s stock price traded up 0.2% on Monday . The company traded as high as $10.01 and last traded at $10.01. 155 shares were traded during mid-day trading, a decline of 100% from the average session volume of 102,408 shares. The stock had previously closed at $9.99.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings assumed coverage on shares of Drugs Made In America Acquisition II in a research report on Monday, March 2nd. They issued a “sell (e)” rating for the company. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Trading Up 0.2%

The stock has a 50-day moving average of $9.98.

Institutional Investors Weigh In On Drugs Made In America Acquisition II

Institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $265,000. Virtu Financial LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $317,000. ABC Arbitrage SA purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $396,000. Deltec Asset Management LLC purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $495,000. Finally, Royal Bank of Canada purchased a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $655,000.

Drugs Made In America Acquisition II Company Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.